TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05495620

Intervention type: DRUG
Intervention: Carfilzomib
Description: Intravenous~carfilzomib, lenalidomide, dexamethasone

Intervention type: DRUG
Intervention: Lenalidomide
Description: Oral

Intervention type: DRUG
Intervention: Dexamethasone
Description: Oral or intravenous
Study: NCT05367219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air sterilizer
Description: The invesitigators will try to remove the smoke with an air sterilizer during the endoscopic gastrointestinal surgery in the Air sterilizer group.
Study: NCT05399641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp
Description: Each day dosing will consist of two 150mg tablets taken BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp
Description: Each day dosing will consist of two 150mg tablets taken BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrexafungerp
Description: Each day dosing will consist of two 150mg tablets taken BID.
Study: NCT04715048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrabotulinumtoxinA
Description: Glabellar line correction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A
Description: Glabellar line correction
Study: NCT04857749

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: As a pre-test to the patients in the group just before starting treatment; Informed Consent Form, Patient Identification Form, CTCAE v5.0 toxicity criteria, Quality of Life Scale will be applied. At the end of the seven weeks, the post-test (measurement tools included in the pre-test) will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Navigation Nursing
Description: With the role of navigator, the nurse contributes to increase the quality of care and to positively affect the physical, psychological and social well-being of the patient. Navigator nurses address patient barriers to care that are complex and often not easily resolved. As a result of the navigation nurses participating in care in the field of oncology; Providing assistance to the side effects of cancer and its treatment, including symptom preventive measures, supporting communication between individuals participating in treatment, preventing delays in treatment, explaining the language of medical treatment, providing psychosocial support, defining and recommending resources.
Study: NCT05987228

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Thymus vulgaris
Description: 500 mg of Thymus vulgaris (capsules) was given orally twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Thymus vulgaris
Description: 500 mg of Thymus vulgaris (capsules) was given orally twice daily
Study: NCT06414083

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diathermy
Description: Diathermy will be used to ablate the randomized sample.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 Laser
Description: CO2 Laser will be used to ablate the randomized sample.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Beam Coagulator
Description: Argon Beam Coagulator will be used to ablate the randomized sample.
Study: NCT05075889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Enrolled subjects will receive Indocyanine Green administered the day prior to surgery during their standard-of-care preoperative appointment
Study: NCT06117007

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Betalains
Description: Betalains extracted from red beetroot (Beta vulgaris) encapsulated in edible capsules.~(25 mg betalains per capsule)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules containing rice hulls. (0 mg betalains per capsule)
Study: NCT05703217

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classical physical therapy with physiotherapy.
Description: C-Mill device: It is possible to stand and walk on the treadmill. The patient is fixed to the moving band by attaching a garment made of corset-like straps, and thanks to this system, the risk of falling of the patient is prevented. There are virtual reality applications on the treadmill floor and on the giant screen opposite: ball collection It provides adaptation of walking to normal life with animal figures, forest or street images, sounds. In classical physical therapy, muscle strengthening, sitting, standing and walking exercises will be performed with physiotherapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classical physical therapy with physiotherapy.
Description: C-Mill device: It is possible to stand and walk on the treadmill. The patient is fixed to the moving band by attaching a garment made of corset-like straps, and thanks to this system, the risk of falling of the patient is prevented. There are virtual reality applications on the treadmill floor and on the giant screen opposite: ball collection It provides adaptation of walking to normal life with animal figures, forest or street images, sounds. In classical physical therapy, muscle strengthening, sitting, standing and walking exercises will be performed with physiotherapy.
Study: NCT05446935

Intervention type: PROCEDURE
Group type: OTHER
Intervention: HITOC
Description: Doxorubicin(dose: 25mg/m2) + Cisplatin(dose: 50mg/m2).
Study: NCT06495957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture group
Description: Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated for 20 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Micro-acupuncture group
Description: After acupuncture, the electrical stimulation is continuously stimulated for 20 minutes. Electrical stimulation is applied briefly for the first 30 seconds.
Study: NCT04934267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise for subjects with JHS
Description: There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise for Controls
Description: There will be two groups, an experimental group with hypermobile individuals, and a control group with individuals that are not hypermobile with normal ranges of motion. All participants will take part in an exercise session with eccentric bicep curls based on their 1 repetition maximum (1-RM), which is the highest amount of weight that they can lift concentrically once. The independent variables are the two groups and the dependent variables are girth, resting arm angle, Pain, McGill Pain Questionnaire, and pressure pain threshold. This groups will perform 1 set of standing eccentric bicep curls order to induce DOMS.Each rep will include a timed 5 second long eccentric component without an concentric component,. The exercise will stop when the participant cannot volitionally keep up with the 5 second count. Prior to exercise, baseline measurements will be taken for all dependent variables. These measures will be taken every day at the same time of day,for the next 4 days.
Study: NCT05853354

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.
Study: NCT06199414

Intervention type: DEVICE
Intervention: Venous Closure
Description: Vascular closure to achieve vascular hemostasis following femoral access with large bore sheaths in catheter ablation procedures

Intervention type: DEVICE
Intervention: Venous Closure
Description: Vascular closure to achieve vascular hemostasis following femoral access with large bore sheaths in catheter ablation procedures
Study: NCT04747262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPACE
Description: SPACE program, an evidence-based protocol that has been proven to be efficent in childhood anxiety disorders and OCD (Lebowitz, 2013; Lebowitz, Omer, Hermes \& Scahill, 2014)
Study: NCT05726149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real UHCDS a-tDCS
Description: Real UHCDS a-tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). UHCDS a-tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
Study: NCT05566821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STRENGTH Outreach Intervention
Description: The STRENGTH outreach intervention is a community-led, strengths-based, and trauma- and violence-informed program to support self-identifying women who experience interpersonal and structural gender-based violence. The outreach intervention aims to support individuals to achieve self-identified priorities.
Study: NCT03734952

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Radiotherapy Program:
Description: Gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified on pre-treatment diagnostic studies. Clinical target volume (CTV) is defined as the primary tumor plus 3cm expansion superiorly and inferiorly along the length of the esophagus and a 1cm radial expansion.The nodal CTV should be defined by a 0.5cm expansion from the nodal GTV.CTV should also include coverage the nodal region(s) in which the involved lymph node(s). A total dose of 45 Gy in 25 fractions is delivered 5 days per week on workdays with intensity modulated radiotherapy (IMRT).
Study: NCT05726149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise
Description: The therapeutic exercise program will include aerobic exercise and muscle strengthening in the same days as UHCDS a-tDCS. The program will last 30-45 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham UHCDS a-tDCS
Description: Sham UHCDS a-tDCS (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for ten sessions (three sessions per week in weeks 1 and 2; and one session per week in weeks 3, 4, 5 and 6). Sham tDCS will be applied for the same time than real UHCDS a-tDCS.
Study: NCT04804124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regularized Sleep Schedule
Description: Participants may maintain a self-selected 8-hour per night sleep schedule as an optional intervention. Participants from any of the three groups may complete the intervention.
Study: NCT05209477

Intervention type: OTHER
Group type: OTHER
Intervention: lung ultrasound assessment
Description: In patients undergoing invasive mechanical ventilation with an arterial oxygen tension on inspired oxygen fraction ratio \< 200 mmHg requiring recruitment maneuver and prone positioning as a rescue therapy, lung aeration will be evaluated at:~1. baseline, in supine position under protective ventilation~2. after two minute of recruitment maneuver in pressure controlled ventilation~3. at 1 hour following prone positioning application
Study: NCT04787653

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Otoband
Description: Participants with Tinnitus will wear the Otoband set at an effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants with Tinnitus will wear the Otoband set at a non-effective power level during a 30 minute time frame and outcome measurements will be recorded in a Google Form.
Study: NCT04804124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regularized Sleep Schedule
Description: Participants may maintain a self-selected 8-hour per night sleep schedule as an optional intervention. Participants from any of the three groups may complete the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regularized Sleep Schedule
Description: Participants may maintain a self-selected 8-hour per night sleep schedule as an optional intervention. Participants from any of the three groups may complete the intervention.
Study: NCT04918147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elotuzumab
Description: Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elotuzumab
Description: Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elotuzumab
Description: Elotuzumab is a humanized recombinant monoclonal antibody (mAb) targeted against SLAMF7, a cell surface glycoprotein.
Study: NCT04874636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT05701644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1K 150mg
Description: Subcutaneously administrate C1K 150mg at Day 1, Day 8, Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1K 300mg
Description: Subcutaneously administrate C1K 300mg at Day 1, Day 8, Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo with the same volume of C1K 300mg
Description: Subcutaneously administrate placebo with the same volume of C1K 300mg at Day 1, Day 8, Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1K 600mg
Description: Subcutaneously administrate C1K 600mg at Day 1, Day 8, Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo with the same volume of C1K 600mg
Description: Subcutaneously administrate placebo with the same volume of C1K 600mg at Day 1, Day 8, Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1K 900mg
Description: Subcutaneously administrate C1K 900mg at Day 1, Day 8, Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo with the same volume of C1K 900mg
Description: Subcutaneously administrate placebo with the same volume of C1K 900mg at Day 1, Day 8, Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1K 1200mg
Description: Subcutaneously administrate C1K 1200mg at Day 1, Day 8, Day 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo with the same volume of C1K 1200mg
Description: Subcutaneously administrate placebo with the same volume of C1K 1200mg at Day 1, Day 8, Day 15
Study: NCT04547530

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: as above

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: as above
Study: NCT05979363

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-BCMA CAR-T
Description: Autologous BCMA-directed CAR-T cells, infusion intravenously at a target dose of 2.0-4.0 x 10\^6 anti-BCMA CAR+T cells/kg.
Study: NCT04918147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for elotuzumab
Description: The placebo for elotuzumab is 0.9% sterile normal saline for injection.
Study: NCT05979363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRD-based regimen
Description: Bortezomib, Lenalidomide and Dexamethasone
Study: NCT05243186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill workstation
Description: walking on a treadmill workstation next to desk with computer and screen

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Treadmill workstation
Description: walking on a treadmill workstation next to desk with computer and screen

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Treadmill workstation
Description: walking on a treadmill workstation next to desk with computer and screen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: Using prescription drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Using prescription drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: Using prescription drug
Study: NCT06414278

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT05993117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G114R VNS system
Description: All patients treated with Rechargeable Implantable Vagus Nerve Stimulation System (G114R)
Study: NCT04601415

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG from handheld device
Description: Acquisition of a single-lead ECG at time of presentation to GP and at echo appointment

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG from handheld device
Description: Acquisition of a single-lead ECG at time of presentation to GP and at echo appointment
Study: NCT05622175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F8IL10
Description: The study consists of a dose escalation of F8IL10 to determine the MTD and the RD when administered intra-articular.~Patients with arthritis flare(s) in large joints (shoulders, elbows, knees and ankles, with the exception of hip) and small joints (metacarpophalangeal joints, proximal interphalangeal joints, second through fifth metatarsal-phalangeal joints, thumb interphalangeal joints, and wrists) defined as per 2010 Rheumatoid Arthritis Classification Criteria \[1\] will be treated with increasing dose of F8IL10 according to the schedule detailed below:~Cohort 1: 0.5 mg F8IL10 Cohort 2: 1 mg F8IL10 Cohort 3: 2.5 mg F8IL10 Cohort 4: 5 mg F8IL10 Cohort 5: 10 mg F8IL10
Study: NCT06154616

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Product
Description: Lactose-free skimmed milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Product: 250
Description: Lactose-free skimmed milk enriched with 250 mg aswaghanda

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Product: 250 + TRP
Description: Lactose-free skimmed milk enriched with 250 mg aswaghanda and tryptophan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Product: 600
Description: Lactose-free skimmed milk enriched with 600 mg aswaghanda
Study: NCT06239766

Intervention type: DIAGNOSTIC_TEST
Intervention: Breast Cancer Risk Assessment
Description: Gail and IBIS Tools will be utilized to calculate mean lifetime breast cancer risk
Study: NCT05717946

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic composed of two bacteria strains: Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell.
Description: We plan to investigate the impact of the Lactobacillus helveticus Rosell and Bifidobacterium longum Rosell on clinical and biochemical parameters in the experimental group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: We plan to investigate the impact of a placebo on clinical and biochemical parameters in the control group.
Study: NCT05083078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab will be administered subcutaneously.
Study: NCT03734952

Intervention type: RADIATION
Group type: OTHER
Intervention: Neoadjuvant Radiotherapy Program:
Description: Gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified on pre-treatment diagnostic studies. Clinical target volume (CTV) is defined as the primary tumor plus 3cm expansion superiorly and inferiorly along the length of the esophagus and a 1cm radial expansion.The nodal CTV should be defined by a 0.5cm expansion from the nodal GTV.CTV should also include coverage the nodal region(s) in which the involved lymph node(s). A total dose of 45 Gy in 25 fractions is delivered 5 days per week on workdays with intensity modulated radiotherapy (IMRT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy Program
Description: Chemotherapy is delivered concomitantly and composed of two cycles of Docetaxel 60mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Neoadjuvant chemotherapy Program
Description: Chemotherapy is delivered concomitantly and composed of two cycles of Docetaxel 60mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy program:
Description: Patients receive esophagectomy in 4-6 weeks after neoadjuvant neoadjuvant chemotherapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Esophagectomy program:
Description: Patients receive esophagectomy in 4-6 weeks after neoadjuvant neoadjuvant chemotherapy